

(19)  **Canadian  
Intellectual Property  
Office**

An Agency of  
Industry Canada

**Office de la Propriété  
Intellectuelle  
du Canada**

Un organisme  
d'Industrie Canada

(11) **CA 2 456 172**

(13) **A1**

(40) 03.04.2003

(43) 03.04.2003

(12)

(21) **2 456 172**

(22) **22.08.2002**

(51) Int. Cl. <sup>7</sup>: **C12N 15/12, C12P 21/02,  
C07K 14/47, C12Q 1/68**

(85) **30.01.2004**

(86) **PCT/JP02/008457**

(87) **WO03/027287**

(30) **2001-290291 JP 21.09.2001**

(71)

**HUMAN CELL SYSTEMS, INC.,  
No. 2 MI Bldg., 1-3-7, Nihombashi  
Horidomecho, Chuo-ku  
103-0012, TOKYO, XX (JP).**

(72)

**ENDOU, HITOSHI (JP).  
KANAI, YOSHIKATSU (JP).  
ENOMOTO, ATSUSHI (JP).**

(74)

**RIDOUT & MAYBEE LLP**

(54) **TRANSPORTEUR D'URATE SPECIFIQUE DU REIN ET GENE ASSOCIE**

(54) **KIDNEY-SPECIFIC URATE TRANSPORTER AND GENE THEREOF**

(57)

It is intended to identify and provide a novel urate transporter gene participating in the urate transport in the kidney and a urate transporter which is a polypeptide encoded by the above gene. Namely, a protein comprising the amino acid sequence represented by SEQ ID NO:1 or an amino acid sequence derived therefrom by deletion, substitution or addition of one to several amino acids and being capable of transporting uric acid and its analogs; and a gene encoding this protein.



Office de la Propriété  
Intellectuelle  
du Canada

Un organisme  
d'Industrie Canada

Canadian  
Intellectual Property  
Office

An agency of  
Industry Canada

CA 2456172 A1 2003/04/03

(21) **2 456 172**

(12) **DEMANDE DE BREVET CANADIEN  
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2002/08/22  
(87) Date publication PCT/PCT Publication Date: 2003/04/03  
(85) Entrée phase nationale/National Entry: 2004/01/30  
(86) N° demande PCT/PCT Application No.: JP 2002/008457  
(87) N° publication PCT/PCT Publication No.: 2003/027287  
(30) Priorité/Priority: 2001/09/21 (2001-290291) JP

(51) Cl.Int.<sup>7</sup>/Int.Cl.<sup>7</sup> C12N 15/12, C12Q 1/68, C07K 14/47,  
C12P 21/02  
(71) Demandeur/Applicant:  
HUMAN CELL SYSTEMS, INC., JP  
(72) Inventeurs/Inventors:  
ENDOU, HITOSHI, JP;  
KANAI, YOSHIKATSU, JP;  
ENOMOTO, ATSUSHI, JP  
(74) Agent: RIDOUT & MAYBEE LLP

(54) Titre : TRANSPORTEUR D'URATE SPECIFIQUE DU REIN ET GENE ASSOCIE  
(54) Title: KIDNEY-SPECIFIC URATE TRANSPORTER AND GENE THEREOF

(57) Abrégé/Abstract:

It is intended to identify and provide a novel urate transporter gene participating in the urate transport in the kidney and a urate transporter which is a polypeptide encoded by the above gene. Namely, a protein comprising the amino acid sequence represented by SEQ ID NO:1 or an amino acid sequence derived therefrom by deletion, substitution or addition of one to several amino acids and being capable of transporting uric acid and its analogs; and a gene encoding this protein.

Canada

<http://opic.gc.ca> • Ottawa-Hull K1A 0C9 • <http://cipo.gc.ca>

OPIC - CIPQ 191

OPIC



CIPQ

## ABSTRACT

It is intended to identify and provide a novel urate transporter gene participating in the urate transport in the kidney and a urate transporter which is a polypeptide encoded by the above gene. Namely, a protein comprising the amino acid sequence represented by SEQ ID NO:1 or an amino acid sequence derived therefrom by deletion, substitution or addition of one to several amino acids and being capable of transporting uric acid and its analogs; and a gene encoding this protein.

## DESCRIPTION

### KIDNEY-SPECIFIC URATE TRANSPORTER AND GENE THEREOF

#### Technical field

The present invention relates to a gene participating in transport of uric acid and analogs thereof or exchange transport of uric acid and the other anion, and a polypeptide encoded by the gene.

#### Background Art

In human race and primates, uric acid which is an organic acid is a final metabolite in purine metabolism in cells, and is excreted mainly from the kidney. In species other than the human race and the primates, it is metabolized to allantoin by an action of uricase in liver, and is excreted from the kidney. Therefore, for the other mammals, it seems that effects of dynamic abnormality of uric acid which is an intermediate product in the kidney on living body are small. Losing the action of uricase in the evolution process seems to be a cause of the fact that the human race has suffered from gout due to hyperuricemia since ancient times.

In humans, when is caused the decrease of uric acid excretion in the kidney causes hyperuricemia, the gout develops at high percentage, which becomes a risk factor for cardiovascular diseases and hypertension. On the other hand, it has been known that the increase of uric acid excretion in the kidney causes renal hypouricemia. Although abnormality of uric acid kinetics is not obvious in these diseases, it has been supposed that urate transporters in the kidney are deeply involved.

The uric acid kinetics in the kidney has been studied by experimental systems

using a removed organ perfusion method and an isolated cell membrane vesicle system. In humans, it has been demonstrated that uric acid freely passes through renal glomerulus and thereafter mechanisms for reabsorption and secretion exist in proximal convoluted tubule. However, by the conventional technique, it has been difficult that urate transport system via cell membrane is analyzed in detail, and it has been desired that the transporter per se is isolated and analyzed.

It has been known that there is a remarkable difference among species in the urate transport in the kidney, and there exist the species where secretion is dominant such as swine and rabbit and the species where the reabsorption is dominant such as human, rat and dog. The swine of the species with secretion dominance excretes from 200 to 300% of uric acid per unit nephron, whereas a human of the species with uric acid reabsorption dominance excretes only about 10% of uric acid per unit nephron. Also, it has been known that responses to uricosuric accelerators and uricosuric inhibitors are different even among the species with reabsorption dominance. Accordingly, since the kinetics of uric acid and the responses to drugs in the kidney are different depending on the species, and uric acid is reciprocally transported, it has not been easy to isolate a molecular entity of the urate transporter though its existence has been assumed.

Among the urate transporters in the kidney, the transporters which reabsorb uric acid from renal tubular lumen have been studied for long time by the experimental system using the isolated cell membrane vesicle system. For the drugs currently used for the patients with hyperuricemia and gout, it is assumed that the transporter which reabsorbs uric acid in the kidney is inhibited. Also, it is forecasted that renal hypouricemia is caused due to gene aberration of this transporter.

Recently, it has been demonstrated that the transporters involved in the

reabsorption of uric acid are exchange transporters of uric acid and various anions in several experiments. For pyrazinamide used as the first-line drug of antituberculous drugs at present, it has been shown that pyrazine carboxylate which is the metabolite of pyrazinamide is an exchange substrate of this exchange transporter and facilitates the reabsorption of uric acid. That is thought to be the cause of hyperuricemia frequently observed in the patients administered the antituberculous drug.

Accordingly, the transporter involved in the reabsorption of uric acid in the kidney is thought to play an important role for internal kinetics of uric acid. It has been anticipated that elucidation of its molecular entity leads to elucidate a mechanism of action of uricosuric accelerators and a cause of renal hypouricemia, and development of new gout curative medicines.

We have previously isolated and reported organic anion transporters, OAT1 (organic anion transporter) (Sekine, T. et al., J. Biol. Chem., 272:18526-18529, 1997), OAT2 (Sekine, T. et al., FEBS Letter, 429:179-182, 1998), OAT3 (Kusuhara, H. et al., J. Biol. Chem., 274:13675-13680, 1999), and OAT4 (Cha, S. H. et al., J. Biol. Chem., 275:4507-4512, 2000) which play central roles in medicament transport in the kidney, liver, brain, placenta and so on. These transporters belonging to OAT family are the transporters capable of transporting many organic anions with different chemical structures, and also perform the transport of various anionic medicaments.

It was not obvious whether the urate transporter belongs to the known transporter family, but since uric acid is a dibasic acid having both pyrimidine structure and imidazole structure and is one of the organic anions, the possibility that the urate transporter phylogenetically belongs to OAT family was anticipated. In OAT family, since OAT4 exists at the side of renal tubular lumen in the kidney and the existence of the transporter involved in the reabsorption of uric acid is also assumed at the side of

renal tubular lumen, it has been also anticipated that the transporter is phylogenetically similar to OAT4.

From these facts, we have anticipated that the urate transporter in the kidney belongs to the organic ion transporter family.

#### Disclosure of the Invention

An object of the present invention is to identify and provide a novel urate transporter gene participating in the urate transport in the kidney and a urate transporter which is a polypeptide encoded by the above gene. Other objects will be apparent from the following description.

#### Brief Description of the Drawings

Figure 1 shows the results of analyzing the expression of URAT1 gene messenger RNA in various organ tissues of human adult and embryo by Northern blotting.

Figure 2 shows the result of time dependency in uric acid uptake experiments by oocytes injected with cRNA of URAT1 gene.

Figure 3 shows the result of concentration dependency in uric acid uptake experiments by oocytes injected with cRNA of URAT1 gene.

Figure 4 shows the result of examining the effects of added salts in uric acid uptake experiments by oocytes injected with cRNA of URAT1 gene.

Figure 5 shows the result of pH dependency in uric acid uptake experiments by oocytes injected with cRNA of URAT1 gene.

Figure 6 shows the result of preincubation with various organic acids in uric acid uptake experiments by oocytes injected with cRNA of URAT1 gene.

Figure 7 shows the result of examining the effect of previously injected unlabeled lactic acid (100 mM, 10 nl) in uric acid uptake experiments by oocytes injected with cRNA of URAT1 gene.

Figure 8 shows the result of examining the effects of addition of various organic acids or analog compounds thereof to the system in uric acid uptake experiments by oocytes injected with cRNA of URAT1 gene.

Figure 9 shows the result of examining the effects of probenecid addition at various concentrations to the system in uric acid uptake experiments by oocytes injected with cRNA of URAT1 gene.

Figure 10 shows the result of examining the effects of losartan addition at various concentrations to the system in uric acid uptake experiments by oocytes injected with cRNA of URAT1 gene.

Figure 11 shows exon-intron structure of URAT1 gene in human genome.

#### Best Mode for Carrying Out the Invention

As described above, the present inventors isolated four organic anion transporters, OTA1, OTA2, OTA3 and OTA4. They have about 40% homology of amino acid sequences each other. On the basis of these sequences, disclosed information of human genome project was searched, and multiple novel gene fragments having homology to OAT1, 2, 3 and 4 were identified. Among them, one novel gene fragment extremely closed to a gene locus position of OAT4 was analyzed, and a site supposed to be an initiation codon was identified. A primer specific for 5' upstream of this initiation codon was made, and isolation of this novel gene was attempted by 3'-RACE (3-rapid amplification of cDNA ends) method using messenger RNA derived from various tissues of humans. As a result, a novel clone (URAT1) which had been



never reported was identified by the 3'-RACE method using human kidney messenger RNA.

The urate transporter1, URAT1 of the present invention has an ability to transport uric acid and its analogs via cell membrane from one side to the other side and further is a urate/anion exchanger by making the anion at the other side of the cell membrane an exchange substrate.

The protein of the present invention includes, for example, those having the amino acid sequence in which one or several amino acids are deleted, substituted or added in the amino acid sequence represented by SEQ ID NO:1, in addition to one having the amino acid sequence represented by SEQ ID NO:1. The amino acids could be deleted, substituted or added to the extent where urate transport activity is not lost, and typically from 1 to about 110 and preferably from 1 to about 55. Such proteins typically have up to 75% and preferably up to 90% homologous amino acid sequences to the amino acid sequence represented by SEQ ID NO:1.

In the present invention, the isolation of the gene by the 3'-RACE method can be carried out typically by making a primer of about 30 bases specific for guanine- or cytosine-rich gene at the 5' upstream of the initiation codon, performing reverse transcription of tissue-derived messenger RNA using an oligo dT primer with an adapter sequence, and subsequently performing PCR (polymerase chain reaction) using the adapter sequence and the gene-specific primer. It is possible to further enhance accuracy of the PCR by the use of heat resistant polymerase with higher fidelity.

The urate transporter gene of the present invention can be isolated and yielded by screening cDNA library prepared using renal tissues or cells in an appropriate mammal as a gene source. The mammals include human in addition to non-human animals such as dog, cattle, horse, goat, sheep, monkey, swine, rabbit, rat

and mouse.

The screening and isolation of the gene can be suitably carried out by homology screening and PCR method.

For the resultant cDNA, it is possible to determine the base sequence by the conventional method, analyze the translation region and determine the amino acid sequence of the protein encoded by this, i.e., URAT1.

It can be verified, for example, by the following method that the obtained gene is cDNA of the urate transporter gene, i.e., a gene product encoded by the cDNA is the urate transporter. The ability to transport (uptake) uric acid into cells can be confirmed by introducing cRNA (complementary RNA) prepared from the obtained URAT1 cDNA into oocyte to express, and measuring the uptake of a substrate into the cells by the conventional uptake experiment using uric acid as the substrate (Sekine, T. et al., *Biochem. Biophys. Res. Commun.*, 251:586-591, 1998).

Also, transport property and substrate specificity of URAT1 can be examined by applying the similar uptake experiment to expressing cells.

Further, the property of URAT1, for example, the property that URAT1 performs the transport with time dependency, substrate selectivity and pH dependency of URAT1 can be examined by applying the similar uptake experiment to the expressing cells.

Homologous genes and chromosomal genes derived from the different tissues or different organisms can be isolated by screening appropriate cDNA libraries or genomic DNA libraries made from the different gene sources using cDNA of the obtained URAT1 gene.

Also, the gene can be isolated from the cDNA library by the conventional PCR method using synthetic primers designed on the basis of the information of the disclosed

base sequence of the gene of the present invention (the base sequence represented by SEQ ID NO:1 or a part thereof).

The DNA libraries such as cDNA library and genomic DNA library can be prepared by the methods described in, for example, "Sambrook, J., Fritsh E. F., and Maniatis, T., "Molecular Cloning" (published by Cold Spring Harbor Laboratory Press in 1989)". Or when there is a commercially available library, it may be used.

To obtain the structure of URAT1 gene on human genome, the genomic DNA library is screened using the obtained URAT1 gene cDNA, and the obtained clones are analyzed. Or the structure may be searched on the basis of the disclosed information of the human genome analysis results using a homology search program.

The urate transporter (URAT1) of the present invention can be produced by gene recombination technology using cDNA which encodes the urate transporter. For example, it is possible to incorporate DNA (cDNA, etc.) which encodes the urate transporter in an appropriate expression vector and introduce the resultant recombinant DNA into appropriate host cells. Expression systems (host vector system) for producing the polypeptide include the expression systems of bacteria, yeast, insect cells and mammalian cells. Among these, to obtain the functional protein, it is desirable to use the insect cells and the mammalian cells.

For example, when the polypeptide is expressed in the mammalian cells, an expression vector is constructed by inserting DNA which encodes the urate transporter in the downstream of an appropriate promoter (e.g., SV40 promoter, LTR promoter, elongation 1 $\alpha$  promoter and the like) in an appropriate expression vector (e.g., retroviral vector, papilloma virus vector, vaccinia virus vector, SV40 type vector and the like). Next, the target polypeptide is produced by transforming appropriate animal cells with the obtained expression vector and culturing transformants in an appropriate medium.

The mammalian cells as the hosts include cell lines such as monkey COS-7 cells, Chinese hamster CHO cells, human HeLa cells and primary culture cells derived from renal tissues, LLC-PK1 cells derived from swine kidney, OK cells derived from opossum kidney, and proximal convoluted tubule S1, S2 and S3 cells derived from mouse.

As the cDNA which encodes the urate transporter URAT1, it is possible to use the cDNA having the base sequence shown in the sequence 1, and further it is possible to design DNA corresponding to the amino acid sequence and use the DNA which encodes the polypeptide without being limited to the above cDNA. In this case, 1 to 6 codons which encodes one amino acid are known, and the codon used may be optionally selected, but it is possible to design the sequence with high expression by considering use frequency of codons in the host utilized for the expression. The DNA with the designed sequence can be acquired by chemical synthesis of DNA, fragmentation and bind of the above cDNA, partial modification of the base sequence and the like. The artificial partial modification and mutagenesis can be carried out by site specific mutagenesis methods (Mark, D. F. et al., Proc. Natl. Acad. Sci. USA, 18:5662-5666, 1984) utilizing primers including synthetic oligonucleotides which encode the desired modification.

The nucleotides (oligonucleotides or polynucleotides) which hybridize with the urate transporter gene of the present invention under a stringent condition can be used as probes to detect the urate transporter gene, and further can be used, for example, as antisense oligonucleotides, ribozymes and decoys to modulate the expression of the urate transporter. As such nucleotides, it is possible to use, for example, the nucleotides typically comprising the partial sequence of consecutive 14 or more bases or the complementary sequence thereof in the base sequence represented by SEQ ID

NO:1. In order to make the hybridization more specific, as the partial sequence, the longer sequence, e.g., the sequence of 20 or more bases or 30 or more bases may be used.

Also, using the urate transporter of the present invention or the polypeptide having immunological equivalence thereto, it is possible to acquire antibodies thereof, and the antibodies can be utilized for the detection and the purification of the urate transporter. The antibody can be produced by using the urate transporter of the invention, a fragment thereof, or a synthetic peptide having the partial sequence thereof and the like as an antigen. The polyclonal antibody can be produced by the conventional method in which the antigen is inoculated to the host animal (e.g., rat or rabbit) and immunized serum is collected, and the monoclonal antibody can be produced by the conventional technology such as a hybridoma method.

Furthermore, the present invention provides a screening method of a substance having uricosuric accelerating action. The protein of the invention works for transporting uric acid into the cells and is deeply involved in the reabsorption of uric acid. Also, as is shown in Figures 6, 8, 9 and 10, it is possible to quantify the accelerating or inhibiting action for uric acid uptake of the screening substance in the system where the protein of the invention is expressed, by adding uric acid to the system, further adding the screening substance thereto, and comparing a uric acid uptake amount with that in the case with no addition of the screening substance. As is shown in Figures 6 and 8, the substances clinically used as uricosuric accelerators have remarkably inhibited the uptake of uric acid in the above experimental system, and thus, it is shown that it become possible to screen the uricosuric accelerating action of the screening substance in this system. As the cells used in this screening system, the cells are not limited to oocytes used in the following experiments, and it is possible to use

various living cells as long as the cells can express the protein of the invention.

Therefore, the present invention provides the method for screening substances having uricosuric regulating action using the protein of the invention. As the uricosuric regulating actions, there are the uricosuric accelerating action and the uricosuric inhibiting action, and those having the uricosuric accelerating action are preferable for the treatment/prevention of hyperuricemia and gout. Thus, the preferable uricosuric regulating action includes the uricosuric accelerating action. Moreover, the present invention provides uricosuric regulators screened by the above screening method. The preferable uric acid regulator includes a uricosuric accelerators. The uricosuric regulator screened by the method of the invention can regulate the uptake of uric acid by the urate transporter involved in the urate transport in the kidney, and therefore can be used as an active ingredient of the medicines for the treatment/prevention of various diseases associated with the reabsorption of uric acid such as hyperuricemia and gout.

It is possible to make the obtained active ingredient a pharmaceutical composition using a pharmacologically acceptable carrier.

### Examples

The present invention is described in more detail by examples below, but these examples do not limit the invention.

In the following examples, unless otherwise specified, respective manipulations were carried out by the methods described in "Sambrook, J., Fritsch E. F., and Maniatis, T., "Molecular Cloning" (published by Cold Spring Harbor Laboratory Press in 1989)" or when using commercially available kits, they were used according to the instructions of the commercially available articles.

**Example 1 : Isolation of kidney-specific urate transporter (URAT1) cDNA and analysis thereof**

On the basis of the base sequence information of OAT1, OAT2, OAT3 and OAT4 already isolated by the present inventors, the disclosed analysis results of the human genome project were searched using the homology search program. As a result, multiple novel gene fragments having homology to OAT1, OAT2, OAT3 and OAT4 were obtained. Among them, one of the novel gene fragments extremely close to the locus position of OAT4 was analyzed, and the site thought to be the initiation codon was identified in it. This initiation codon was identified by comparing the novel gene fragments with gene sequences of OAT1 and OAT4.

A primer specific for the 5' upstream region of the predicted initiation codon was made using 28 bases, and the isolation of this novel gene was attempted by 3'-RACE (3'-rapid amplification of cDNA ends) method using messenger RNA derived from various tissues of human. As a result, a monoclonal (URAT1) was obtained by the 3'-RACE method using human kidney messenger RNA. A single band obtained by PCR method was subcloned in pCRII-TOPO vector using TA cloning method, and further subcloned in pcDNA 3.1(+) vector which was the expression vector. As a result, a novel cDNA (URAT1 cDNA) which has urate transport activity was obtained (for analysis of transport function, see the followings.).

Determination of the base sequence of the cDNA (URAT1 cDNA) obtained by the above was carried out using specific primers by an automatic sequencer (manufactured by Applied Biosystems) (described in SEQ ID NO:1).

The expression of URAT1 gene was analyzed in various tissues of human (Northern blotting) (Figure 1). Full length URAT1 cDNA was labeled with <sup>32</sup>P-dCTP,

and using this as a probe, hybridization was carried out using filters (manufactured by Clontech) blotting RNA extracted from various human tissues. The hybridization was carried out overnight in a hybridization solution comprising the labeled full length URAT1 cDNA, and the filters were washed with 0.1xSSC comprising 0.1% SDS at 65°C. As a result of Northern blotting, an intensive band was detected in the renal tissue. In human embryonic tissues, the band was detected in the kidney.

#### Example 2: Analysis of urate transporter functions

From plasmid comprising URAT1 cDNA, cRNA (RNA complementary to cDNA) was prepared in vitro using T7 RNA polymerase (see Sekine, T., et al., J. Biol. Chem., 272:18526-18529, 1997).

The resultant cRNA was injected in oocytes of platanna, and uptake experiments of the radiolabeled uric acid in these oocytes were carried out according to the method already reported (Sekine, T., et al., J. Biol. Chem., 272:18526-18529, 1997). As a result, it was found that the oocytes in which URAT1 was expressed showed uptake of [ $^{14}\text{C}$ ] uric acid as shown in Figure 2. The oocytes in which URAT1 was expressed showed time dependency in the uptake of [ $^{14}\text{C}$ ] uric acid. This indicated that not only URAT1 was bound to uric acid but also was the transporter to transport it into the cells. No uptake of [ $^{14}\text{C}$ ] PAH (para-amino hippuric acid) and [ $^{14}\text{C}$ ] TEA (tetraethylammonium) which are a representative substrate of the organic ion transporter family was observed (not shown).

Michaelis-Menten dynamic experiment in urate transport by URAT1 was carried out. Concentration dependency of uric acid in the transport by URAT1 was studied by examining change of uptake amounts of uric acid at various concentrations by URAT1. The uptake experiment of the radiolabeled uric acid was carried out using



oocytes injected with URAT1 cRNA according to the method described above. As a result (Figure 3),  $K_m$  value (Michaelis constant number) of the uric acid uptake was approximately  $372 \pm 25 \mu\text{M}$ .

The effect of various electrolytes on the urate transport by URAT1 was studied (Figure 4). When extracellular sodium was replaced with lithium, choline and N-methyl-D-glucamine (NMDG), the urate transport via URAT1 was not changed. It was demonstrated that URAT1 was the extracellular sodium-independent urate transporter. When extracellular potassium ions were completely replaced with sodium (0-K<sup>+</sup> in Figure 4) and sodium was completely replaced with the potassium ions (96 mM KCl), the urate transport was not also changed, which was demonstrated that URAT1 was cell membrane potential-independent. When extracellular chloride ions were replaced with gluconic acid, the uptake of uric acid was significantly increased. From the experimental system using the isolated cell membrane vesicle system, the presence of the exchanger for uric acid and chloride was shown at the side of renal tubular lumen in human kidney. Thus, this experimental result suggests that chloride might be the exchange substrate of uric acid.

The pH dependency in the urate transport by URAT1 was studied. As shown in Figure 5, when the extracellular pH was acidified, the urate transport in the oocyte injected with URAT1 cRNA was increased, but this seems to be caused by non-specific absorption of uric acid in the oocytes injected with water (control). The substantial urate transport (URAT1-control) was not changed depending on pH.

#### Example 3: Study on exchange substrate of uric acid in the urate transporter

From the experimental system using the isolated cell membrane vesicle system, it has been suggested that monocarboxylic acids such as lactic acid and nicotinic acid

can be the exchange substrate of uric acid in the uric acid/anion exchanger in the human kidney. In order to study the exchange substrate of uric acid in URAT1, the oocytes were preincubated with these monocarboxylic acids (1 mM), para-amino hippuric acid and ketoglutaric acid, and subsequently the transport of uric acid was measured (Figure 6). When the oocytes were preincubated with 1mM of pyrazine carboxylic acid and nicotinic acid (3-pyridine carboxylic acid), the uptake of uric acid was significantly increased in the oocytes injected with URAT1 cRNA. On the other hand, when the oocytes were preincubated with para-amino hippuric acid and ketoglutaric acid which were not monocarboxylic acids, the uptake of uric acid was not facilitated. The above results indicate that monocarboxylic acids such as pyrazine carboxylic acid and nicotinic acid are the exchange substrate of uric acid.

In Figure 6, when the oocytes were preincubated with lactic acid which was monocarboxylic acid, the uptake of uric acid was not facilitated. It was thought to be occurred because the incorporated lactic acid was transported outside of the cells via a pathway other than URAT1 due to abundant expression of endogenous lactate transporters in the oocytes. Also, it was anticipated that low affinity of lactic acid to URAT1 as shown below was also one of the causes. Therefore, 100 nl of 100 mM non-radiolabeled L-lactic acid was precedently injected in the oocytes, and then the uptake of the radiolabeled uric acid was observed (Figure 7). When lactic acid was precedently injected, the significantly high uptake of uric acid was observed compared to the case where water was injected. Even when para-amino hippuric acid and ketoglutaric acid were injected, no change was observed compared to the case where water was injected (not shown).

From the results in Figures 6 and 7, URAT1 is the exchanger of uric acid and monocarboxylic acid. Pyrazinamide which is an antituberculous drug is metabolized

to become pyrazine carboxylic acid, which is then excreted into urine, whereas it is said to facilitate the reabsorption of uric acid. The above result shows that as a result of the exchange of uric acid and pyrazine carboxylic acid in URAT1, the uptake of uric acid is facilitated. Accordingly the mechanism to cause hyperuricemia has been demonstrated which is a side effect of pyrazinamide which is the antituberculous drug.

#### Example 4: Screening of inhibitory substance for urate transporter

In order to further study substrate selectivity of URAT1, in the uptake experiment system of [ $^{14}\text{C}$ ] uric acid by the oocytes injected with URAT1 cRNA, various substances were added to the system and their effects were examined (inhibitory experiments). The uptake experiment of [ $^{14}\text{C}$ ] uric acid was carried out using the oocytes injected with URAT1 cRNA according to the method described above (Figures 8, 9 and 10). The uptake of 50  $\mu\text{M}$  [ $^{14}\text{C}$ ] uric acid was measured under the condition at pH 7.4 in the presence and absence of various compounds (unlabeled) at the concentrations shown in Figure 8. As a result, various monocarboxylic acids (L-lactic acid, D-lactic acid, nicotinic acid, pyrazine carboxylic acid) significantly inhibited the transport of [ $^{14}\text{C}$ ] uric acid by URAT1 (Figure 8). Ketoglutaric acid which was dicarboxylic acid and could be the exchange substrate of OAT1 did not inhibit under the condition at pH 7.4. Pyrazine dicarboxylic acid which had a similar structure to pyrazine carboxylic acid showed slightly weak inhibitory effect. Anionic and cationic substances such as para-amino hippuric acid and tetraethylammonium did not show any inhibitory action (Figure 8).

Medicines used for the treatment of hyperuricemia, such as probenecid, benz-bromarone, sulfinpyrazon and phenylbutazone, significantly inhibited the uptake of uric acid in URAT1. Losartan which is a drug for the treatment of hypertension and

has been known to have the uricosuric accelerating action, significantly inhibited the uptake of uric acid by URAT1 as well as its metabolite, EXP-3174. From the above results, URAT1 is an action site of representative uricosuric accelerators clinically used at present.

The inhibitory effects on the uptake action of uric acid via URAT1 were examined using probenecid and losartan at various concentrations (Figures 9 and 10). Their IC<sub>50</sub> values were approximately 50  $\mu$ M and 20  $\mu$ M, respectively.

#### Example 5: Structural analysis of URAT1 gene

The structure of URAT1 gene in the human genome was analyzed. The disclosed information of the human genome analysis results was searched using the homology search program, and the exon-intron structure of the URAT1 gene was demonstrated. As shown in Figure 11, the URAT1 gene was consisted of 10 exons and the initiation codon existed in the first exon.

#### Industrial Applicability

The kidney-specific urate transporter which selectively transports uric acid of the present invention and its gene enable to study in vitro the transport of uric acid and its analogs at the site where the transporter is expressed and forecast internal kinetics of the compounds based on the study. Uric acid is the factor deeply involved in hyperuricemia and gout, and it appears that the invention of the transporter will contribute the elucidation of pathogenesis of hyperuricemia and gout in future. The transporter has the action to reabsorb uric acid in the kidney, and it appears that the transporter will contribute the elucidation of causative gene of renal hypouricemia where reabsorption mechanism of uric acid is lost. Additionally, the elucidation of

novel compounds inhibiting the function of the transporter and control factors modulating the expression can contribute the development of new therapeutic methods for hyperuricemia and gout.

SEQUENCE LISTING

<110> Human Cell Systems, Inc.

<120> KIDNEY-SPECIFIC URATE TRANSPORTER AND GENE THEREOF

<130> JA921603

<150> JP 2001-290291

<151> 2001-09-21

<160> 2

<170> PatentIn Ver. 2.1

<210> 1

<211> 2642

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (148)..(1809)

<400> 1

gccccgagtc tgtgaagcct agccgcctggg ctggagaagc cactglgggc accaccgtgg 60

gggaaacagg ccggtgccc tggcctcttt gccctgggcc agcccttgig aagtgggccc 120

ctcttctggg ccccttgagt aggttcc atg gca ttt tct gaa ctc ctg gac ctc 174

Met Ala Phe Ser Glu Leu Leu Asp Leu

1

5

gtg ggt ggc ctg ggc agg ttc cag gtt ctc cag acg atg gct ctg atg 222

Val Gly Gly Leu Gly Arg Phe Gln Val Leu Gln Thr Met Ala Leu Met

10

15

20

25

gtc tcc atc atg tgg ctg tgt acc cag agc atg ctg gag aac ttc tct 270

Val Ser Ile Met Trp Leu Cys Thr Gln Ser Met Leu Glu Asn Phe Ser

30

35

40

gcc gcc gtg ccc agc cac cgc tgc tgg gca ccc ctc ctg gac aac agc 318

Ala Ala Val Pro Ser His Arg Cys Trp Ala Pro Leu Leu Asp Asn Ser

45

50

55

acg gct cag gcc agc atc cta ggg agc ttg agt cct gag gcc ctc ctg 366

Thr Ala Gln Ala Ser Ile Leu Gly Ser Leu Ser Pro Glu Ala Leu Leu

60

65

70

gct att tcc atc ccg ccg ggc ccc aac cag agg ccc cat cag tgc cgc 414

Ala Ile Ser Ile Pro Pro Gly Pro Asn Gln Arg Pro His Gln Cys Arg

75

80

85

cgc ttc cgc cag cca cag tgg cag ctc ttt gac ccc aat gcc acg gcc 462

Arg Phe Arg Gln Pro Gln Trp Gln Leu Leu Asp Pro Asn Ala Thr Ala

90

95

100

105

acc agc tgg agc gag gcc gac acg gag ccg tgt glg gal ggc tgg gtc 510  
 Thr Ser Trp Ser Glu Ala Asp Thr Glu Pro Cys Val Asp Gly Trp Val

110

115

120

tat gac cgc agc atc ttc acc tcc aca atc glg gcc aag tgg aac ctc 558  
 Tyr Asp Arg Ser Ile Phe Thr Ser Thr Ile Val Ala Lys Trp Asn Leu

125

130

135

gtg tgt gac tct cac gct ctg aag ccc atg gcc cag tcc atc tac ctg 606  
 Val Cys Asp Ser His Ala Leu Lys Pro Met Ala Gln Ser Ile Tyr Leu

140

145

150

gct ggg att ctg gtg gga gct gct gcg tgc ggc cct gcc tca gac agg 654  
 Ala Gly Ile Leu Val Gly Ala Ala Ala Cys Gly Pro Ala Ser Asp Arg

155

160

165

ttt ggg cgc agg ctg gtg cta acc tgg agc tac ctt cag atg gct gtg 702  
 Phe Gly Arg Arg Leu Val Leu Thr Trp Ser Tyr Leu Gln Met Ala Val  
 170 175 180 185

atg ggt acg gca gct gcc ttc gcc cct gcc ttc ccc glg tac tgc ctg 750  
 Met Gly Thr Ala Ala Ala Phe Ala Pro Ala Phe Pro Val Tyr Cys Leu

190

195

200

ttc cgc ttc ctg ttg gcc ttt gcc glg gca ggc gtc atg atg aac acg 798  
 Phe Arg Phe Leu Leu Ala Phe Ala Val Ala Gly Val Met Met Asn Thr

205

210

215



ggc act ctc ctg atg gag tgg acg gcg gca cgg gcc cga ccc ttg gtg 846  
 Gly Thr Leu Leu Met Glu Trp Thr Ala Ala Arg Ala Arg Pro Leu Val

220

225

230

atg acc ttg aac tct ctg ggc ttc agc ttc ggc cat ggc ctg aca gct 894  
 Met Thr Leu Asn Ser Leu Gly Phe Ser Phe Gly His Gly Leu Thr Ala

235

240

245

gca gtg gcc tac ggt gtg cgg gac tgg aca ctg ctg cag ctg gtg gtc 942  
 Ala Val Ala Tyr Gly Val Arg Asp Trp Thr Leu Leu Gln Leu Val Val

250

255

260

265

tcg gtc ccc ttc ttc ctc tgc ttt ttg tac tcc tgg tgg ctg gca gag 990  
 Ser Val Pro Phe Phe Leu Cys Phe Leu Tyr Ser Trp Trp Leu Ala Glu

270

275

280

tcg gca cga tgg ctc ctc acc aca ggc agg ctg gat tgg ggc ctg cag 1038  
 Ser Ala Arg Trp Leu Leu Thr Thr Gly Arg Leu Asp Trp Gly Leu Gln

285

290

295

gag ctg tgg agg gtg gct gcc atc aac gga aag ggg gca gtg cag gac 1086  
 Glu Leu Trp Arg Val Ala Ala Ile Asn Gly Lys Gly Ala Val Gln Asp

300

305

310

acc ctg acc cct gag gtc ttg ctt tca gcc atg cgg gag gag ctg agc 1134  
 Thr Leu Thr Pro Glu Val Leu Leu Ser Ala Met Arg Glu Glu Leu Ser

315

320

325

atg ggc cag cct cct gcc agc ctg ggc acc ctg ctc cgc atg ccc gga 1182

Met Gly Gln Pro Pro Ala Ser Leu Gly Thr Leu Leu Arg Met Pro Gly  
 330 335 340 345

ctg cgc ttc cgg acc tgt atc tcc acg ttg tgc tgg ttc gcc ttt ggc 1230  
 Leu Arg Phe Arg Thr Cys Ile Ser Thr Leu Cys Trp Phe Ala Phe Gly  
 350 355 360

ttc acc ttc ttc ggc ctg gcc ctg gac ctg cag gcc ctg ggc agc aac 1278  
 Phe Thr Phe Phe Gly Leu Ala Leu Asp Leu Gln Ala Leu Gly Ser Asn  
 365 370 375

atc ttc ctg ctc caa atg ttc att ggt gtc gtg gac atc cca gcc aag 1326  
 Ile Phe Leu Leu Gln Met Phe Ile Gly Val Val Asp Ile Pro Ala Lys  
 380 385 390

atg ggc gcc ctg ctg ctg ctg agc cac ctg ggc cgc cgc ccc acg ctg 1374  
 Met Gly Ala Leu Leu Leu Leu Ser His Leu Gly Arg Arg Pro Thr Leu  
 395 400 405

gcc gca tcc ctg ttg ctg gcg ggg ctc tgc att ctg gcc aac acg ctg 1422  
 Ala Ala Ser Leu Leu Leu Ala Gly Leu Cys Ile Leu Ala Asn Thr Leu  
 410 415 420 425

gtg ccc cac gaa atg ggg gct ctg cgc tca gcc ttg gcc gtg ctg ggg 1470  
 Val Pro His Glu Met Gly Ala Leu Arg Ser Ala Leu Ala Val Leu Gly  
 430 435 440

ctg ggc ggg gtg ggg gct gcc ttc acc tgc atc acc atc tac agc agc 1518  
 Leu Gly Gly Val Gly Ala Ala Phe Thr Cys Ile Thr Ile Tyr Ser Ser

445	450	455	
gag ctc ttc ccc acf gfg ctc agg atg acg gca gfg ggc ttg ggc cag			1566
Glu Leu Phe Pro Thr Val Leu Arg Met Thr Ala Val Gly Leu Gly Gln			
460	465	470	
atg gca gcc cgl gga gga gcc atc ctg ggg cct ctg gtc cgg ctg ctg			1614
Met Ala Ala Arg Gly Gly Ala Ile Leu Gly Pro Leu Val Arg Leu Leu			
475	480	485	
ggi gtc cat ggc ccc tgg ctg ccc ttg ctg gfg tat ggg acg gfg cca			1662
Gly Val His Gly Pro Trp Leu Pro Leu Leu Val Tyr Gly Thr Val Pro			
490	495	500	505
gtg ctg agt ggc ctg gcc gca ctg ctt ctg ccc gag acc cag agc ttg			1710
Val Leu Ser Gly Leu Ala Ala Leu Leu Leu Pro Glu Thr Gln Ser Leu			
510	515	520	
ccg ctg ccc gac acc atc caa gat gfg cag aac cag gca gta aag aag			1758
Pro Leu Pro Asp Thr Ile Gln Asp Val Gln Asn Gln Ala Val Lys Lys			
525	530	535	
gca aca cat ggc acg ctg ggg aac tct gtc cta aaa tcc aca cag ttt			1806
Ala Thr His Gly Thr Leu Gly Asn Ser Val Leu Lys Ser Thr Gln Phe			
540	545	550	
tag cctcctgagg aacctgcgat gggacggica gaggaagaga ctcttctgt			1859

tcctcggaga aggcaggagg aaagcaaaga cctccatlc cagaggccca gaggcctgcc 1919

tcgagggcc ccactctccc ccagggcctgc cccctccaggt gagccctgcc cctctcacag 1979

tccaaggggc cccctcaat actgaagggg aaaaggacag ttgatlggc aggaggigac 2039

ccaglgcacc aicacccctgc cctgccctcg tggcttcgga gagcagaggg gtcaggccca 2099

ggggaacgag ctggccctgc caacctctg ctgactccg cactgccact tgcctcccca 2159

cacccgtcca cctgccaga gctcagagct aaccaccatc calggccaag accctcctta 2219

gcctcacaca agcagtagag tctcagctcc acagctttac ccagaagccc tgaagccctg 2279

gcccciggcc cctccccaig tccctccagg cctcagccac ctgcccgcga catcctctgc 2339

cgtctgtccc ctcccaccc tcatccctga ccgactccac ttaaccccca aaccagccc 2399

ccctccagg ggctcagggc cagccctgaga tgcctgtgaa acicctacc acagttacag 2459

ccacaagcct gccctctccc accctgccag cctatgagtt ccagagggt tggggcagtc 2519

ccaagacccc atgtcccagc tccccacaca ggcctgggcc agagaggcat tggctcgagg 2579

gattgaataa agaaacaaat gaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2639

aaa

2642

&lt;210&gt; 2

&lt;211&gt; 553

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

```

Met Ala Phe Ser Glu Leu Leu Asp Leu Val Gly Gly Leu Gly Arg Phe
  1             5             10             15
Gln Val Leu Gln Thr Met Ala Leu Met Val Ser Ile Met Trp Leu Cys
          20             25             30
Thr Gln Ser Met Leu Glu Asn Phe Ser Ala Ala Val Pro Ser His Arg
          35             40             45
Cys Trp Ala Pro Leu Leu Asp Asn Ser Thr Ala Gln Ala Ser Ile Leu
          50             55             60
Gly Ser Leu Ser Pro Glu Ala Leu Leu Ala Ile Ser Ile Pro Pro Gly
          65             70             75             80
Pro Asn Gln Arg Pro His Gln Cys Arg Arg Phe Arg Gln Pro Gln Trp
          85             90             95
Gln Leu Leu Asp Pro Asn Ala Thr Ala Thr Ser Trp Ser Glu Ala Asp
          100            105            110
Thr Glu Pro Cys Val Asp Gly Trp Val Tyr Asp Arg Ser Ile Phe Thr
          115            120            125
Ser Thr Ile Val Ala Lys Trp Asn Leu Val Cys Asp Ser His Ala Leu
          130            135            140
Lys Pro Met Ala Gln Ser Ile Tyr Leu Ala Gly Ile Leu Val Gly Ala
          145            150            155            160
Ala Ala Cys Gly Pro Ala Ser Asp Arg Phe Gly Arg Arg Leu Val Leu
          165            170            175
Thr Trp Ser Tyr Leu Gln Met Ala Val Met Gly Thr Ala Ala Ala Phe

```

180	185	190	
Ala Pro Ala Phe Pro Val Tyr Cys Leu Phe Arg Phe Leu Leu Ala Phe			
195	200	205	
Ala Val Ala Gly Val Met Met Asn Thr Gly Thr Leu Leu Met Glu Trp			
210	215	220	
Thr Ala Ala Arg Ala Arg Pro Leu Val Met Thr Leu Asn Ser Leu Gly			
225	230	235	240
Phe Ser Phe Gly His Gly Leu Thr Ala Ala Val Ala Tyr Gly Val Arg			
245	250	255	
Asp Trp Thr Leu Leu Gln Leu Val Val Ser Val Pro Phe Phe Leu Cys			
260	265	270	
Phe Leu Tyr Ser Trp Trp Leu Ala Glu Ser Ala Arg Trp Leu Leu Thr			
275	280	285	
Thr Gly Arg Leu Asp Trp Gly Leu Gln Glu Leu Trp Arg Val Ala Ala			
290	295	300	
Ile Asn Gly Lys Gly Ala Val Gln Asp Thr Leu Thr Pro Glu Val Leu			
305	310	315	320
Leu Ser Ala Met Arg Glu Glu Leu Ser Met Gly Gln Pro Pro Ala Ser			
325	330	335	
Leu Gly Thr Leu Leu Arg Met Pro Gly Leu Arg Phe Arg Thr Cys Ile			
340	345	350	
Ser Thr Leu Cys Trp Phe Ala Phe Gly Phe Thr Phe Phe Gly Leu Ala			
355	360	365	
Leu Asp Leu Gln Ala Leu Gly Ser Asn Ile Phe Leu Leu Gln Met Phe			
370	375	380	
Ile Gly Val Val Asp Ile Pro Ala Lys Met Gly Ala Leu Leu Leu Leu			
385	390	395	400
Ser His Leu Gly Arg Arg Pro Thr Leu Ala Ala Ser Leu Leu Leu Ala			
405	410	415	

Gly Leu Cys Ile Leu Ala Asn Thr Leu Val Pro His Glu Met Gly Ala  
                   420                          425                          430  
 Leu Arg Ser Ala Leu Ala Val Leu Gly Leu Gly Gly Val Gly Ala Ala  
                   435                          440                          445  
 Phe Thr Cys Ile Thr Ile Tyr Ser Ser Glu Leu Phe Pro Thr Val Leu  
                   450                          455                          460  
 Arg Met Thr Ala Val Gly Leu Gly Gln Met Ala Ala Arg Gly Gly Ala  
 465                          470                          475                          480  
 Ile Leu Gly Pro Leu Val Arg Leu Leu Gly Val His Gly Pro Trp Leu  
                   485                          490                          495  
 Pro Leu Leu Val Tyr Gly Thr Val Pro Val Leu Ser Gly Leu Ala Ala  
                   500                          505                          510  
 Leu Leu Leu Pro Glu Thr Gln Ser Leu Pro Leu Pro Asp Thr Ile Gln  
                   515                          520                          525  
 Asp Val Gln Asn Gln Ala Val Lys Lys Ala Thr His Gly Thr Leu Gly  
                   530                          535                          540  
 Asn Ser Val Leu Lys Ser Thr Gln Phe  
 545                          550

## Claims

1. A protein comprising the amino acid sequence represented by SEQ ID NO:1 or an amino acid sequence derived therefrom by deletion, substitution or addition of one to several amino acids and being capable of transporting uric acid and its analogs.
2. The protein according to claim 1 which is derived from human.
3. The protein according to claim 1 or 2 which is derived from organs, tissues or cultured cells.
4. A gene encoding the protein according to claim 1.
5. DNA comprising the base sequence represented by SEQ ID NO:1 or DNA hybridizing with the DNA under a stringent condition and encoding a protein being capable of transporting uric acid and its analogs or exchanging uric acid and the other anion.
6. The gene according to claim 5, which is derived from human.
7. The gene according to claim 5 or 6, which is derived from organs, tissues or cultured cells.
8. The gene according to any of claims 4 to 7 or a plasmid comprising a gene encoding a protein of the gene.



9. The plasmid according to claim 8, wherein the plasmid is an expression plasmid.
10. Host cells transformed with the plasmid according to claim 8 or 9.
11. Nucleotides comprising a partial sequence of consecutive 14 bases or more in the base sequence represented by SEQ ID NO:1 or a complementary sequence thereof.
12. The nucleotides according to claim 11, used as a probe to detect the gene encoding the protein being capable of transporting uric acid and its analogs or exchanging uric acid and other anion.
13. The nucleotides according to claim 11, used to modulate the expression of the gene encoding the protein being capable of transporting uric acid and its analogs or exchanging uric acid and other anion.
14. An antibody against the protein according to any of claims 1 to 3.
15. A method for detecting an action of a subject substance as a substrate for an ability to transport uric acid of the protein and its analogs or exchange uric acid and other anion using the protein according to any of claims 1 to 3.
16. A method for screening substances having a uricosuric regulating action using the protein according to any of claims 1 to 3.

17. A uricosuric regulating agent capable of being screened by the method according to claim 16.
18. A method for changing kinetics of uric acid and its analogs transported by the protein in the kidney, by modulating an ability to transport uric acid of the protein and its analogs or exchange the uric acid and other anion, using the protein according to any of claims 1 to 3, a specific antibody thereof, a function accelerating substance thereof or a function inhibiting substance thereof.
19. A method for changing effects of uric acid and its analogs transported by the protein on kinetics in the kidney, by modulating an ability to transport uric acid of the protein and its analogs or exchange the uric acid and other anion, using the protein according to any of claims 1 to 3, a specific antibody thereof, a function accelerating substance thereof or a function inhibiting substance thereof.
20. A method for changing effects of uric acid and its analogs transported by the protein on total blood concentrations, by modulating an ability to transport uric acid of the protein and its analogs or exchange the uric acid and other anions, using the protein according to any of claims 1 to 3, a specific antibody thereof, a function accelerating substance thereof or a function inhibiting substance thereof.
21. A method for detecting and changing effects of uric acid and its analogs transported by the protein on kinetics in the kidney, by excessively expressing the protein in the certain cells or by modulating an ability to transport uric acid of the

protein existing in the cells and its analogs, using the protein according to any of claims 1 to 3, a specific antibody thereof, a function accelerating substance thereof or a function inhibiting substance thereof, and cDNA (complementary DNA) encoding the same.

Application number / numéro de demande: JP02/08457


Figures: 1,

Pages: \_\_\_\_\_

Unscannable items  
received with this application  
(Request original documents in File Prep. Section on the 10<sup>th</sup> floor)

Documents reçu avec cette demande ne pouvant être balayés  
(Commander les documents originaux dans la section de préparation des dossiers au  
10<sup>ème</sup> étage)

FIG. 2



**FIG. 3**




FIG. 4




FIG. 5






FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11

## EXON-INTRON ORGANIZATION OF URAT1 GENE

EXON		INTRON			EXON	
No.	SIZE(bp)	3' BINDING SITE	5' BINDING SITE	SIZE(bp)	No.	5' BINDING SITE
1	586	...GTGGCCAAG	GTAGGGCCT...	819	1	...TCCCATCAG
2	104	...CTCAGACAG	GTGAGTACC...	521	2	...GTGCCGCAG
3	155	...GCACCTCTCC	GTAGGTCCTC...	74	3	...TCCCTTGCAG
4	169	...GTACTCTCTG	GTGGGTGCT...	4247	4	...CCACTTAAG
5	124	...ACCCCTGAG	GTAAGGCTG...	167	5	...CCTCCACAG
6	116	...GTTGTGCTG	GTAGATGCC...	751	6	...CTGCCCCAG
7	215	...TGCCCCACG	GTGAGGGGG...	475	7	...TACCCACAG
8	109	...TGTGCTCAG	GTGAGGCTG...	258	8	...CATTGGCAG
9	204	...GCAGAAOCA	GTGAGTGA...	548	9	...CCTGAACAG
10	857	...ACAAATGAA			10	GGCAGTAAA...